Literature DB >> 17911628

CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease.

Matthew R Olson1, Steven M Varga.   

Abstract

Vaccination of children with a formalin-inactivated (FI) respiratory syncytial virus (RSV) vaccine led to exacerbated disease including pulmonary eosinophilia following a natural RSV infection. Immunization of BALB/c mice with FI-RSV or a recombinant vaccinia virus (vv) expressing the RSV attachment (G) protein (vvG) results in a pulmonary Th2 response and eosinophilia after RSV challenge that closely mimics the RSV vaccine-enhanced disease observed in humans. The underlying causes of RSV vaccine-enhanced disease remain poorly understood. We demonstrate here that RSV M2-specific CD8 T cells reduce the Th2-mediated pathology induced by vvG-immunization and RSV challenge in an IFN-gamma-independent manner. We also demonstrate that FI-RSV immunization does not induce a measurable RSV-specific CD8 T cell response and that priming FI-RSV-immunized mice for a potent memory RSV-specific CD8 T cell response abrogates pulmonary eosinophilia after subsequent RSV challenge. Our results suggest that the failure of the FI-RSV vaccine to induce a CD8 T cell response may have contributed to the development of pulmonary eosinophilia and augmented disease that occurred in vaccinated individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911628     DOI: 10.4049/jimmunol.179.8.5415

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  68 in total

1.  Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.

Authors:  Ruihong Zeng; Huixian Zhang; Yan Hai; Yuxiu Cui; Lin Wei; Na Li; Jianxun Liu; Caixia Li; Ying Liu
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Regulation of cytokine production by virus-specific CD8 T cells in the lungs.

Authors:  Ross B Fulton; Matthew R Olson; Steven M Varga
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

3.  Fixing a failed vaccine.

Authors:  Steven M Varga
Journal:  Nat Med       Date:  2009-01       Impact factor: 53.440

4.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 5.  Viral infections in lung transplant recipients.

Authors:  Pali Dedhiya Shah; John F McDyer
Journal:  Semin Respir Crit Care Med       Date:  2010-03-30       Impact factor: 3.119

6.  Fas ligand is required for the development of respiratory syncytial virus vaccine-enhanced disease.

Authors:  Matthew R Olson; Steven M Varga
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

7.  Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.

Authors:  Tessie B McNeely; Najaf A Shah; Arthur Fridman; Amita Joshi; Jonathan S Hartzel; Ravi S Keshari; Florea Lupu; Mark J DiNubile
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination.

Authors:  Elaine M Castilow; Steven M Varga
Journal:  Future Virol       Date:  2008       Impact factor: 1.831

10.  beta-Glucan oligosaccharide enhances CD8(+) T cells immune response induced by a DNA vaccine encoding hepatitis B virus core antigen.

Authors:  Jing Wang; Shengfu Dong; Chunhong Liu; Wei Wang; Shuhui Sun; Jianxin Gu; Yuan Wang; Diana Boraschi; Di Qu
Journal:  J Biomed Biotechnol       Date:  2010-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.